ES2578302T3 - Compuestos de 5,6-dihidro-1H-piridin-2-ona - Google Patents
Compuestos de 5,6-dihidro-1H-piridin-2-ona Download PDFInfo
- Publication number
- ES2578302T3 ES2578302T3 ES08733076.7T ES08733076T ES2578302T3 ES 2578302 T3 ES2578302 T3 ES 2578302T3 ES 08733076 T ES08733076 T ES 08733076T ES 2578302 T3 ES2578302 T3 ES 2578302T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- alkylene
- aryl
- heterocyclyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/18—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Un compuesto de Fórmula I**Fórmula** en la que X es N o CR3, A es**Fórmula** o**Fórmula** el anillo B es arilo o heterociclilo de 6 miembros, opcionalmente sustituido con 1-3 restos R1, en el que R1 es H, halo, nitro, -CHR4-S(O)2R5, -C(S(O)2R5)>=CHR4-, -NR5R6, -NR4S(O)2R5 o -NR4S(O)2NR5R6, en los que R4, R5 y R6 son independientemente H, alquilo C1-C6, cicloalquilo C3-C8, C(O)O-(alquilo C1-C6), arilo o heterociclilo, o R4 y R5 o R5 y R6 se combinan con el/los átomo/s al/a los que están unidos para formar un anillo hetericiclilo de 5 o 6 miembros, R2 es H, alquilo C1-C6, cicloalquilo C3-C8, -alquilen C1-C6(cicloalquilo C3-C8), -alquilen C1-C6(arilo), -alquilen C1-C6(heterociclilo), arilo o heterociclilo, R3 es H, halo o alquilo C1-C6, Z es -(CR13R14)n- u O, n es 1 o 2, R7 y R8 son independientemente H o alquilo C1-C6, R9, R10, R11, R12, R13, R14, R15 y R16 son independientemente H, alquilo C1-C6, hidroxi o halo, en la que los restos alquilo, alquileno, arilo, cicloalquilo o heterociclilo anteriores proporcionados en R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15 y R16 están cada uno opcional e independientemente sustituidos con de 1 a 3 sustituyentes seleccionados entre alquilamina, amino, arilo, cicloalquilo, heterociclilo, alquilo C1-C6, haloalquilo C1-C6, hidroxialquilo C1-C6, alcoxi C1-C6, alquilamina C1-C6, dialquilamina C1-C6, alquenilo C2-C6 o alquinilo C2-C6, en el que cada uno de los mismos puede estar interrumpido por uno o más heteroátomos, carboxilo, ciano, halo, hidroxi, ceto, nitro, -C(O)OH, -C(O)NH2, -C(O)(alquilamina C1-C6), -C(O)(dialquilamina C1-C6), -C(O)2-(alquilo C1-C6), -C(O)2-(cicloalquilo C3-C8), -C(O)2-(arilo), -C(O)2-(heterociclilo), -C(O)2-(alquilen C1-C6)arilo, -C(O)2-(alquilen C1-C6)heterociclilo, -C(O)2-(alquilen C1-C6)cicloalquilo, -C(O)(alquilo C1-C6), -C(O)(cicloalquilo C3-C8), -C(O)(arilo), -C(O)(heterociclilo), -C(O)(alquilen C1-C6)arilo, -C(O)(alquilen C1-C6)heterociclilo y -C(O)(alquilen C1-C6)cicloalquilo, en el que cada uno de los sustituyentes opcionales anteriores puede estar opcionalmente sustituido adicionalmente con de 1 a 5 sustituyentes seleccionados entre amino, ciano, halo, hidroxi, nitro, alquilamina C1-C6, dialquilamina C1-C6, alquilo C1-C6, alcoxi C1-C6, alquenilo C1-C6 e hidroxialquilo C1-C6, en el que cada alquilo está opcionalmente sustituido con uno o más sustituyentes halo, o una sal o un estereoisómero farmacéuticamente aceptable del mismo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US90747807P | 2007-04-03 | 2007-04-03 | |
US907478P | 2007-04-03 | ||
PCT/US2008/059164 WO2008124450A1 (en) | 2007-04-03 | 2008-04-02 | 5,6-dihydro-1h-pyridin-2-one compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2578302T3 true ES2578302T3 (es) | 2016-07-22 |
Family
ID=39831340
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES08733076.7T Active ES2578302T3 (es) | 2007-04-03 | 2008-04-02 | Compuestos de 5,6-dihidro-1H-piridin-2-ona |
Country Status (23)
Country | Link |
---|---|
US (6) | US7939524B2 (es) |
EP (1) | EP2129224B1 (es) |
JP (2) | JP5739662B2 (es) |
KR (1) | KR101542516B1 (es) |
CN (2) | CN104086540B (es) |
AR (1) | AR065927A1 (es) |
AU (1) | AU2008237364B2 (es) |
BR (1) | BRPI0809685A2 (es) |
CA (1) | CA2682584C (es) |
CL (1) | CL2008000959A1 (es) |
EA (1) | EA017685B1 (es) |
ES (1) | ES2578302T3 (es) |
HK (2) | HK1137119A1 (es) |
IL (2) | IL201312A (es) |
MX (1) | MX2009010564A (es) |
MY (1) | MY157961A (es) |
NZ (1) | NZ580445A (es) |
PE (1) | PE20090220A1 (es) |
TN (1) | TN2009000398A1 (es) |
TW (2) | TWI427079B (es) |
UA (1) | UA100120C2 (es) |
WO (1) | WO2008124450A1 (es) |
ZA (1) | ZA200907673B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7462611B2 (en) | 2006-06-22 | 2008-12-09 | Anadys Pharmaceuticals, Inc. | Pyrro[1,2-b]pyridazinone compounds |
UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
WO2009152166A1 (en) * | 2008-06-10 | 2009-12-17 | Anadys Pharmaceuticals, Inc. | [1,2,4]thiadiazine 1,1-dioxide compounds |
WO2010042834A1 (en) | 2008-10-09 | 2010-04-15 | Anadys Pharmaceuticals, Inc. | A method of inhibiting hepatitis c virus by combination of a 5,6-dihydro-1h-pyridin-2-one and one or more additional antiviral compounds |
TW201026675A (en) * | 2008-10-09 | 2010-07-16 | Anadys Pharmaceuticals Inc | 5,6-dihydro-1H-pyridin-2-one compounds |
RU2012121847A (ru) | 2009-10-28 | 2013-12-10 | Анадис Фармасьютикалз, Инк. | Дейтерированные соединения 5, 6-дигидро-1н-пиридин-2-она |
MX2012007076A (es) | 2009-12-18 | 2012-07-20 | Boehringer Ingelheim Int | Terapia combinada de hcv. |
WO2012158271A1 (en) | 2011-04-06 | 2012-11-22 | Anadys Pharmaceuticals, Inc. | Bridged polycyclic compounds as antiviral agents |
SG195288A1 (en) | 2011-06-07 | 2013-12-30 | Anadys Pharmaceuticals Inc | [1,2,4]thiadiazine 1,1-dioxide compounds for lowering serum uric acid |
EP2858637A1 (en) * | 2012-06-12 | 2015-04-15 | F. Hoffmann-La Roche AG | Combination of therapeutic agents for treating hcv infection |
EP2943468B1 (en) | 2013-01-14 | 2017-03-01 | F. Hoffmann-La Roche AG | A novel process for the preparation of n-(4-nitro-2-sulfamoyl-phenyl)-malonamic acid methyl ester and n-(4-amino-2-sulfamoyl-phenyl)-malonamic acid methyl ester |
PL3068782T3 (pl) * | 2013-11-13 | 2018-12-31 | Vertex Pharmaceuticals Incorporated | Sposoby wytwarzania inhibitorów replikacji wirusów grypy |
WO2016130043A1 (ru) * | 2015-02-13 | 2016-08-18 | Александ Васильевич ИВАЩЕНКО | Бензо[1,2,4]тиадиазиновые ингибиторы репликации вируса гепатита в и фармацевтическая композиция для лечения гепатита в |
KR20220119529A (ko) | 2016-06-02 | 2022-08-29 | 애브비 인코포레이티드 | 글루코코르티코이드 수용체 작용제 및 이의 면역접합체 |
AU2018374634A1 (en) | 2017-12-01 | 2020-05-28 | Abbvie Inc. | Glucocorticoid receptor agonist and immunoconjugates thereof |
CN113292574B (zh) * | 2020-02-21 | 2022-05-03 | 四川大学 | 一类手性多环的托品烷化合物及其制备方法和用途 |
JP7435515B2 (ja) * | 2021-03-17 | 2024-02-21 | 株式会社村田製作所 | 部品収容装置 |
Family Cites Families (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4171361A (en) * | 1977-03-31 | 1979-10-16 | Eli Lilly And Company | 1-Substituted-3-amino-6,7-dialkoxy-1H-1,2,4-benzothiadiazine-1-oxides |
US4889851A (en) * | 1986-11-21 | 1989-12-26 | Fujisawa Pharmaceutical Co, Ltd. | Benzothiadiazine compounds, and pharmaceutical composition comprising the same |
WO2001085172A1 (en) | 2000-05-10 | 2001-11-15 | Smithkline Beecham Corporation | Novel anti-infectives |
AR036081A1 (es) | 2001-06-07 | 2004-08-11 | Smithkline Beecham Corp | Compuesto de 1,2-dihidroquinolina, su uso para preparar una composicion farmaceutica, metodos para prepararlo y compuestos del acido 2-aminobenzoico n-alquilado de utilidad como intermediarios en dichos metodos |
WO2003059356A2 (en) | 2001-10-30 | 2003-07-24 | Smithkline Beecham Corporation | Novel anti-infectives |
US20050075331A1 (en) * | 2003-10-06 | 2005-04-07 | Pratt John K. | Anti-infective agents |
BR0315897A (pt) | 2002-11-01 | 2008-05-13 | Abbott Lab | agentes antiinfecciosos |
JP4738172B2 (ja) * | 2002-11-01 | 2011-08-03 | アボット・ラボラトリーズ | 抗感染薬 |
US7601709B2 (en) * | 2003-02-07 | 2009-10-13 | Enanta Pharmaceuticals, Inc. | Macrocyclic hepatitis C serine protease inhibitors |
BRPI0509207A (pt) * | 2004-03-24 | 2007-08-28 | Janssen Pharmaceutica Nv | moduladores canabinóides de tetraidro-indazol |
US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
RU2007110531A (ru) * | 2004-08-23 | 2008-09-27 | Ф.Хоффманн-Ля Рош Аг (Ch) | Гетероциклические противовирусные соединения |
JP2008526687A (ja) * | 2004-12-17 | 2008-07-24 | アナディス ファーマシューティカルズ インク | ピリダジノン化合物 |
WO2006093801A1 (en) * | 2005-02-25 | 2006-09-08 | Abbott Laboratories | Thiadiazine derivatives useful as anti-infective agents |
KR20080000642A (ko) | 2005-04-21 | 2008-01-02 | 니뽄 신야쿠 가부시키가이샤 | 프탈라지논 유도체 및 그 의약 |
CN101189230A (zh) * | 2005-05-04 | 2008-05-28 | 弗·哈夫曼-拉罗切有限公司 | 抗病毒的杂环化合物 |
US7462611B2 (en) * | 2006-06-22 | 2008-12-09 | Anadys Pharmaceuticals, Inc. | Pyrro[1,2-b]pyridazinone compounds |
US20080090814A1 (en) | 2006-06-22 | 2008-04-17 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
CL2007003587A1 (es) | 2006-12-12 | 2008-07-04 | Anadys Pharmaceuticals Inc | Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c. |
WO2008073987A1 (en) | 2006-12-12 | 2008-06-19 | Anadys Pharmaceuticals, Inc. | Saturated fused [1,2-b] pyridazinone compounds |
US20080188466A1 (en) | 2006-12-21 | 2008-08-07 | Anadys Pharmaceuticals, Inc. | Pyridazinone compounds |
US20080275032A1 (en) | 2006-12-29 | 2008-11-06 | Yuefen Zhou | Pyridazinone compounds |
US20080227774A1 (en) | 2007-03-15 | 2008-09-18 | Frank Ruebsam | 5,5-disubstituted-indolizinone compounds |
UA100120C2 (en) | 2007-04-03 | 2012-11-26 | Анадис Фармасьютикалз, Инк. | 5,6-dihydro-1h-pyridin-2-one compounds |
US7834009B2 (en) | 2007-08-27 | 2010-11-16 | Anadys Pharmaceuticals, Inc. | 4-hydroxy-5,6-dihydro-1H-pyridin-2-one compounds |
-
2008
- 2008-02-04 UA UAA200910844A patent/UA100120C2/ru unknown
- 2008-04-02 CN CN201410217806.6A patent/CN104086540B/zh not_active Expired - Fee Related
- 2008-04-02 WO PCT/US2008/059164 patent/WO2008124450A1/en active Application Filing
- 2008-04-02 PE PE2008000597A patent/PE20090220A1/es active IP Right Grant
- 2008-04-02 EP EP08733076.7A patent/EP2129224B1/en active Active
- 2008-04-02 CL CL2008000959A patent/CL2008000959A1/es unknown
- 2008-04-02 TW TW097111924A patent/TWI427079B/zh active
- 2008-04-02 MX MX2009010564A patent/MX2009010564A/es active IP Right Grant
- 2008-04-02 JP JP2010502271A patent/JP5739662B2/ja not_active Expired - Fee Related
- 2008-04-02 BR BRPI0809685A patent/BRPI0809685A2/pt not_active Application Discontinuation
- 2008-04-02 ES ES08733076.7T patent/ES2578302T3/es active Active
- 2008-04-02 CA CA2682584A patent/CA2682584C/en active Active
- 2008-04-02 KR KR1020097023036A patent/KR101542516B1/ko active IP Right Grant
- 2008-04-02 EA EA200970916A patent/EA017685B1/ru unknown
- 2008-04-02 CN CN200880018225.2A patent/CN101677563B/zh not_active Expired - Fee Related
- 2008-04-02 MY MYPI20094109A patent/MY157961A/en unknown
- 2008-04-02 NZ NZ580445A patent/NZ580445A/en not_active IP Right Cessation
- 2008-04-02 AU AU2008237364A patent/AU2008237364B2/en not_active Ceased
- 2008-04-02 US US12/061,499 patent/US7939524B2/en active Active
- 2008-04-02 TW TW103101356A patent/TWI481588B/zh not_active IP Right Cessation
- 2008-04-03 AR ARP080101383A patent/AR065927A1/es active IP Right Grant
-
2009
- 2009-09-30 TN TNP2009000398A patent/TN2009000398A1/fr unknown
- 2009-10-01 IL IL201312A patent/IL201312A/en active IP Right Grant
- 2009-11-02 ZA ZA2009/07673A patent/ZA200907673B/en unknown
-
2010
- 2010-05-13 HK HK10104667.2A patent/HK1137119A1/zh not_active IP Right Cessation
-
2011
- 2011-03-08 US US13/043,167 patent/US8101800B2/en not_active Expired - Fee Related
-
2012
- 2012-01-23 US US13/356,063 patent/US8236948B2/en not_active Expired - Fee Related
- 2012-08-06 US US13/567,667 patent/US8546602B2/en active Active
-
2013
- 2013-04-11 IL IL225694A patent/IL225694A/en active IP Right Grant
- 2013-09-30 US US14/041,376 patent/US8765741B2/en active Active
-
2014
- 2014-06-10 US US14/300,306 patent/US9156832B2/en not_active Expired - Fee Related
-
2015
- 2015-02-10 HK HK15101490.6A patent/HK1201822A1/xx not_active IP Right Cessation
- 2015-02-16 JP JP2015027744A patent/JP5934403B2/ja not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2578302T3 (es) | Compuestos de 5,6-dihidro-1H-piridin-2-ona | |
ES2618630T3 (es) | Composiciones terapéuticas y métodos de uso relacionados | |
AR054214A1 (es) | Compuestos derivados de 1, 1 - dioxotiadiazina, composiciones farmaceuticas que los contienen y su uso en el tratamiento de la infeccion por el virus de la hepatitis c. | |
PE20090276A1 (es) | Compuestos derivados de imidazoquinolina como moduladores de tlr7 | |
RS53569B1 (en) | NEW COMPOUNDS AND COMPOSITIONS, AND PROCEDURES FOR USE | |
PE20091236A1 (es) | Derivados de pirimidina como immunomoduladores de tlr7 | |
PE20091575A1 (es) | Derivados bifenilo como inhibidores del virus de la hepatitis c | |
CO6260076A2 (es) | Derivados de uracilo o timina para el tratamiento de la hepatitis c | |
AR057408A1 (es) | Agonistas del receptor de niacina composiciones que contienen tales compuestos y procedimientos para tratamiento | |
AR086181A2 (es) | Metodo para preparar inhibidores macrociclicos inhibidores de serina proteasas del virus de la hepatitis c | |
AR063022A1 (es) | Derivados de indol antagonistas del receptor de glucagon, composiciones farmaceuticas que los contienen y usos para tratar diabetes mellitus tipo 2 y estados patologicos relacionados. | |
AR044152A1 (es) | Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad | |
CO5590957A2 (es) | Amino-1,3,5-triazinas sustituidas en n con radicales biciclicos quirales, procedimiento para su preparacion, composiciones de las mismas y su uso como herbicidas y reguladores del crecimiento de las plantas | |
ECSP067013A (es) | 2-quinolil-oxazoles sustituidos útiles como inhibidores de pde4 | |
AR042996A1 (es) | Un procedimiento de obtencion de derivados de malonamida y medicamentos que los contienen. | |
CO6210770A2 (es) | Compuestos 2-aril-5-heterociclil-ciclohexan-1, 3 diona y su uso como herbicidas | |
AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
PE20140863A1 (es) | Compuestos de benceno sustituidos con arilo o heteroarilo | |
AR047098A1 (es) | Derivados de arilanilina como agonistas del receptor adrenergico beta2 | |
AR069435A1 (es) | Derivados de aminotiazol, proceso para la obtencion de los mismos, composiciones farmaceuticas y su uso como inhibidores de la fbpasa | |
AR035548A1 (es) | Compuestos organicos | |
ES2271615T3 (es) | N-aril-2-oxazolidinona-5-carboxamidas y sus derivados y su uso como antibacterianos. | |
AR065985A1 (es) | Derivados de arilisoxazolina,composiciones que los contienen y usos de los mismos como agentes insecticidas y acaricidas. | |
PE20090630A1 (es) | Derivados de indol 2-carboxi sustituidos y metodos para su utilizacion | |
PE20130375A1 (es) | Compuestos de triazolopiridinas y triazolopirazinas inhibidores de c-met y composiciones de los mismos |